Ersbøll AK, Sengupta K, Pukkala E, Bolin K, Aas E, Emneus M, Ramey DR, Brady JE, Mines D, Aasbjerg K, Vestergaard C, Gislason G, Born AP, Kjærulff TM. Desloratadine exposure and incidence of seizure: a nordic post-authorization safety study using a new-user cohort study design, 2001-2015. Drug Saf. 2021 Nov;44(11):1231-42. doi: 10.1007/s40264-021-01106-7
Mines D, Fireman B, Lee J, Go AS. Venlafaxine use was not associated with an increased risk of sudden cardiac death. Presented at the 23rd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2007. Quebec City, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2007 Aug; 16(Suppl 2):S7.
Mines D, Novelli L. Letter to the editor. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis. 2007 Feb 15;44(4):619-20.
Rubino A, Roskell NS, Tennis P, Mines D, Weich S, Andrews E. Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study. BMJ. 2007 Feb 3;334(7587):242-5.
Mines D, Gu Y, Novelli L, Lui Q, Gelfand J. Risk of CNS demyelinating diseases among patients with psoriasis and rheumatoid arthritis. Poster presented at the 2007 59th Annual Meeting of the American Academy of Neurology; May 2007. Boston, MA. [abstract] Neurology. 2007; 68(12, Suppl 1):A165.
Umscheid CA, Maguire MG, Pines JM, Everett WW, Baren JM, Townsend RR, Mines D, Szyld D, Gross R. The prevalence of and risk factors associated with untreated hypertension in ED patients. Poster presented at the 2007 Society for Academic Emergency Medicine Conference; May 2007. Chicago, IL. [abstract] Acad Emerg Med. 2007; 14(5 Suppl 1):S117.